PROTARA THERAPEUTICS, INC.
TARA US74365U1079
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Levy Richard S O |
3.19 USD |
20,000 Bought |
63,800 USD |
14/05/2025 | 14/05/2025 |
Levy Richard S O |
3.19 USD |
20,000 Bought |
63,800 USD |
14/05/2025 | 14/05/2025 |
Levy Richard S O |
3.19 USD |
20,000 Bought |
63,800 USD |
14/05/2025 | 14/05/2025 |
Zummo Jacqueline SR OFF |
4.53 USD |
21,224 Sold |
96,145 USD |
26/03/2025 | 26/03/2025 |
Opaleye Management Inc. O |
1.71 USD |
6,500 Sold |
11,108 USD |
11/09/2024 | 12/09/2024 |
Opaleye Management Inc. O |
1.71 USD |
119,801 Sold |
204,728 USD |
11/09/2024 | 12/09/2024 |
Opaleye Management Inc. O |
1.71 USD |
1,600 Sold |
2,743 USD |
11/09/2024 | 11/09/2024 |
Opaleye Management Inc. O |
1.71 USD |
31,000 Sold |
53,137 USD |
11/09/2024 | 11/09/2024 |
Opaleye Management Inc. O |
1.77 USD |
1,500 Sold |
2,654 USD |
09/09/2024 | 10/09/2024 |
Opaleye Management Inc. O |
1.77 USD |
24,000 Sold |
42,456 USD |
09/09/2024 | 10/09/2024 |